Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Employees: 1-10
Investment Stage: Series B
Portfolio 58
| Date | Name | Website | Total Raised | Location |
| 07.08.2023 | Gracell Bi... | gracellbio... | $250M | China, Jia... |
| 11.07.2023 | @Septerna_... | septerna.c... | $290M | United Sta... |
| 17.10.2022 | Odyssey Th... | odysseytx.... | $487M | United Sta... |
| 27.08.2021 | Willow | onewillow.... | - | - |
| 17.08.2021 | Nuvalent | nuvalent.c... | $187.23M | United Sta... |
| 17.08.2021 | Graphite B... | graphitebi... | $195.75M | United Sta... |
| 17.08.2021 | Interius | interiusbi... | $76M | United Sta... |
| 17.08.2021 | century_tx | centurytx.... | $410M | United Sta... |
| 17.08.2021 | Boundless ... | boundlessb... | $251.4M | United Sta... |
| 17.08.2021 | Ventyx Bio... | ventyxbio.... | $165M | United Sta... |
Show more
Mentions in press and media 3
| Date | Title | Description | Source |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture In the Unite... | vator.tv/n... |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and ... | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways wi... | marketscre... |
| 09.01.2021 | Visen Pharmaceuticals Closes $150M Series B Financing | Visen Pharmaceuticals, a Shangai, China-based biotech company focused on developing and commercializ... | finsmes.co... |